logo
logo
LivaNova PLC

LivaNova PLC

NASDAQ•LIVN
CEO: Mr. Alex Shvartsburg C.M.A.
セクター: Healthcare
業種: Medical - Devices
上場日: 2015-10-19
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
連絡先情報
20 Eastbourne Terrace, London, W2 6LG, United Kingdom
44-20-3325-0660
www.livanova.com
時価総額
$3.49B
PER (TTM)
-16.0
31.5
配当利回り
--
52週高値
$67.92
52週安値
$32.48
52週レンジ
89%
順位51Top 71.3%
3.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$357.80M+12.47%
直近4四半期の推移

EPS

$0.49-19.67%
直近4四半期の推移

フリーCF

$62.18M+89.29%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Revenue Exceeds $1 Billion Nine months revenue reached $1.027B USD, marking a 10.3% increase driven by strong global sales across segments.
Operating Cash Flow Rises Cash provided by operating activities totaled $171.943M for nine months, significantly up from $104.331M previous period.
Cardiopulmonary Revenue Strong Cardiopulmonary net revenue grew 15.3% to $578.810M for nine months, fueled by Essenz system sales and consumables demand.
Early Term Debt Repayment Company executed $200M early repayment on Term Facilities in May 2025, resulting in $2.7M loss on extinguishment.

リスク要因

Nine Month Net Loss Reported Nine months ended September 30, 2025 resulted in a net loss of $(273.377)M, contrasting sharply with prior year net income.
SNIA Environmental Liability Exposure SNIA environmental liability recorded $394.587M current liability following Italian Supreme Court decision; interest accrues currently.
Cybersecurity Costs Incurred Total direct costs related to the November 2023 cybersecurity incident reached $13.1M through September 30, 2025.
3T Device Litigation Provision Product liability provision stands at $19.8M as of September 30, 2025, reflecting probable and estimable claims related to 3T device.

見通し

Evaluating New Tax Disclosures Adopting ASU 2023-09 expands income tax disclosures starting December 15, 2024; Company currently evaluating material effect.
VNS Therapy Clinical Validation CORE-VNS study data validated VNS Therapy effectiveness for DRE; Company initiated CMS reconsideration for TRD coverage.
Iran Revenue Disclosed Activities in Iran generated $2.1M revenue and $1.0M net profit for the quarter, consistent with applicable sanctions laws.

同業比較

売上高 (TTM)

Surgery Partners, Inc.SGRY
$3.29B
+10.1%
LivaNova PLCLIVN
$1.35B
+8.6%
Prestige Consumer Healthcare Inc.PBH
$1.10B
-1.3%

粗利益率 (最新四半期)

IDEAYA Biosciences, Inc.IDYA
99.5%
+0.0pp
Apellis Pharmaceuticals, Inc.APLS
94.7%
+11.7pp
Alphatec Holdings, Inc.ATEC
69.9%
+1.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CDTX$5.61B-18.6-60.1%0.4%
SRRK$4.76B-15.0-122.0%26.7%
LIVN$3.49B-16.0-18.8%19.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.6%
緩やかな成長
4四半期純利益CAGR
-21.7%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月24日
|
EPS:$0.80
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $357.80M+12.5%
    |
    EPS: $0.49-19.7%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $352.52M+10.7%
    |
    EPS: $0.50+66.7%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $316.86M+7.4%
    |
    EPS: $-6.01+670.5%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $1.25B+8.7%
    |
    EPS: $1.17+254.5%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月31日|
    売上高: $318.12M+11.2%
    |
    EPS: $0.61-535.7%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $318.58M+8.4%
    |
    EPS: $0.30+1400.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月3日|
    売上高: $294.91M+12.0%
    |
    EPS: $-0.78-657.1%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $1.15B+12.9%
    |
    EPS: $0.33+120.5%
    予想を下回る